NW-7-295

NW-7-295 is an investigational protein degrader developed by Guangzhou Lupeng Pharmaceutical, utilizing Proteolysis-Targeting Chimera (PROTAC) technology to target Bruton's tyrosine kinase (BTK). Unlike traditional BTK inhibitors that only block the protein's enzymatic activity, NW-7-295 is designed to recruit an E3 ubiquitin ligase to BTK, leading to its ubiquitination and subsequent degradation by the 26S proteasome. This mechanism of action may provide enhanced efficacy and overcome resistance mutations, such as C481S, which often limit the effectiveness of covalent BTK inhibitors. The drug is currently in development for the treatment of various hematological malignancies, particularly B-cell cancers.